Faculty Collaboration Database

Gastrointestinal chronic graft-versus-host disease: management options. J Oncol Pharm Pract 2007 Mar;13(1):49-51

Date

07/11/2007

Pubmed ID

17621568

DOI

10.1177/1078155207077264

Scopus ID

2-s2.0-34250202254 (requires institutional sign-in at Scopus site)   1 Citation

Abstract

Chronic graft-versus-host disease (GVHD) is a common and debilitating condition afflicting a number of allogeneic stem cell recipients more than 100 days after their transplant. Limited options are available for the acute management of patients with severe gastrointestinal (GI) symptoms including gastric bleeding. Along with increased immunosuppression and aggressive supportive care, we report here the use of aminocaproic acid in the management of patients with GI bleeding resulting from severe GVHD. The use of aminocaproic acid enabled us to reduce the frequency and number of blood product transfusions required to manage our patient. Anti-fibrinolytic agents may therefore serve as useful adjunctive but underutilized therapy in the management of patients with severe GI chronic GVHD.

Author List

Awan F, Hamadani M

Author

Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Aminocaproates
Anti-Ulcer Agents
Antifibrinolytic Agents
Chronic Disease
Combined Modality Therapy
Erythrocyte Transfusion
Gastrointestinal Hemorrhage
Graft vs Host Disease
Humans
Immunosuppressive Agents
Leukemia, Myeloid, Acute
Male
Peripheral Blood Stem Cell Transplantation
Proton Pump Inhibitors